Cigna Corporation, a major U.S. healthcare player, is transforming its Pharmacy Benefit Management (PBM) model. Analysts remain generally positive.
Market cap ranged from $65B to $82B, currently at $75.72B. Bond.az analysis suggests the stock is undervalued.
The PBM transition is on track, with no derailment from FTC settlement or legislation.
The new PBM model mitigates policy risks, seen as forward-thinking.
Earnings estimates: FY1 $29.60-$30.30/share, FY2 $30.70-$33.75/share.
2026 MLR guidance indicates limited stop-loss margin improvement.
Regulatory environment is complex but hasn't changed long-term margin expectations.
Medicare Advantage market growth expected, with margin improvement in 2026.
Client profitability analysis affects competitors like Centene.
Competition in stop-loss market limits pricing power.
New PBM model offers competitive advantage against regulatory pressures.
